このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PH-ILDにおけるミリバデルガットの安全性と有効性を評価する研究 (WINDWARD)

2026年9月17日 更新者:Foresee Pharmaceuticals Co., Ltd.

間質性肺疾患に伴う肺高血圧症(PH-ILD)患者を対象としたアルデヒドデヒドロゲナーゼ 2 活性化剤ミリバデルガットの安全性と有効性を評価する多国籍第 2 相無作為化二重盲検プラセボ対照複数回投与試験

The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat. The main question it aims to answer is if mirivadelgat will improve pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a way to measure blood flow in the lungs.

Researchers will compare mirivadelgat to a placebo (a look-alike capsule that contains no drug) to see if mirivadelgat works to improve the symptoms of PH-ILD. The symptoms of PH-ILD that are being looked at are exercise tolerance, heart function, and general well-being.

Participants will:

Take mirivadelgat or a placebo once a day for 12 weeks

Visit the clinic once every 4 weeks for checkups and tests

Receive phone calls every one or two weeks to check on how things are going

調査の概要

詳細な説明

The study is a phase 2, multinational, double-blind, 3-arm study to evaluate the safety and efficacy of mirivadelgat, an aldehyde dehydrogenase 2 activator, in adult subjects (aged 18 to 85 years) with PH-ILD. Participants must have a confirmed diagnosis of ILD as defined by the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and/or Latin American Thoracic Society (ALAT) guidelines (Raghu, 2018). The diagnosis is based on a HRCT either performed at screening or within 180 days prior to screening or a historical surgical biopsy (or other appropriate tissue sampling (e.g., cryobiopsy)) and an RHC performed at screening.

To be eligible for the study, a participant must be willing to undergo a Right Heart Catheterization (RHC) during screening and at the Week 12 Visit (at the end of study treatment). Participants on chronic treatment for underlying pulmonary diseases must be on a stable/optimized dose for ≥30 days prior to screening and have been receiving treatment for ≥90 days prior to screening.

The study will enroll approximately 126 participants, assuming a drop-out rate of 20%, to obtain 99 evaluable participants (33 evaluable subjects in each cohort).

Study visits will include a Screening Visit; Visit 2 (Study Day 1); Weeks 2, 3, 4, 6, 8,10, and 12 Visits (+/ 3 days); and a safety Follow-up Visit (+/ 3 days) after the Week 12 Visit. Visits on Weeks 2, 3, 6, and 10 will be conducted by phone calls.

研究の種類

介入

入学 (推定)

126

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Banja Luka、ボスニア・ヘルツェゴビナ、78000
        • まだ募集していません
        • University Clinical Centre of the Republic of Srpska
      • Sarajevo、ボスニア・ヘルツェゴビナ、71000
        • まだ募集していません
        • Clinical Center of the University of Sarajevo
      • Kaohsiung City、台湾、813
        • 終了しました
        • Kaohsiung Veterans General Hospital
      • Taipei、台湾、104
        • 募集
        • MacKay Memorial Hospital
        • 主任研究者:
          • Yih-Jer Wu, MD
        • コンタクト:
    • Taiwan
      • Hualien City、Taiwan、台湾、970
        • 募集
        • Hualien Tzu Chi Hospital
        • 主任研究者:
          • Wei-Hsin Liu, M.D.
        • コンタクト:
      • Kaohsiung City、Taiwan、台湾
        • 終了しました
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Taichung、Taiwan、台湾、407219
        • 募集
        • Taichung Veterans General Hospital
        • 主任研究者:
          • Pin-Kuei Fu, M.D.
        • コンタクト:
      • Tainan、Taiwan、台湾、704
        • 終了しました
        • National Cheng Kung University Hospital
      • Taipei、Taiwan、台湾、11217
        • 募集
        • Taipei Veterans General Hospital
        • コンタクト:
        • 主任研究者:
          • Shih-Hsien Sung, M.D.
        • コンタクト:
      • Taipei、Taiwan、台湾、100225
        • 募集
        • National Taiwan University Hospital
        • 主任研究者:
          • Ping-Hung Kuo, M.D.
        • コンタクト:
      • Taoyuan City、Taiwan、台湾
        • 募集
        • Chang Gung Memorial Hospital - Linkou Branch
        • 主任研究者:
          • Wan-Jing Ho, M.D.
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. A clinical diagnosis of PH-ILD.

  2. Participant voluntarily gives informed consent.

  3. Male or female participants aged between 18 and 85 years at the time of signing informed consent.

  4. Participants must agree to practice protocol-defined birth control during the study period, unless they meet criteria for not being of childbearing potential.

    • Male participants with female partners of childbearing potential must practice protocol- defined birth control for the duration of treatment and at least 96 hours after discontinuing the IP.

    • Female participants of childbearing of potential (including those <1-year post-menopausal) must practice protocol-defined birth control during the conduct of the study and for 30 days after the last dose of IP (males only during exposure to IP).

    • Female participants not of childbearing potential (as defined below) are eligible for enrolment without contraception requirements:

      1. Post-menopausal women (at least 12 months with no menses without an alternative medical cause); in women <45 years of age, a high follicle-stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy; OR
      2. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR
      3. Have a congenital or acquired condition that prevents childbearing.
  5. The participant has a confirmed diagnosis of any form of interstitial lung disease based on high-resolution computed tomography (HRCT) of the chest within 180 days prior to screening or at screening or a historical surgical biopsy (or other appropriate tissue sampling (e.g., cryobiopsy). The participant can have other findings (e.g., emphysema) if this is not the predominant feature on the scan.

  6. Participants have undergone RHC during the screening period with the following documented parameters:

    • Pulmonary vascular resistance (PVR) ≥4 Wood units and
    • Pulmonary capillary wedge pressure (PCWP) of ≤12 mmHg [if PVR ≥4 Wood units to <6.25 Wood units] or PCWP ≤15 mmHg [if PVR ≥6.25 Wood units] Note: If a reliable PCWP cannot be obtained, left ventricular end-diastolic pressure (LVEDP), measured via left heart catheterization (LHC), will be acceptable, with the same numerical thresholds as the PCWP criterion: LVEDP of ≤12 mmHg [if PVR ≥4 to <6.25 Wood units], or LVEDP ≤15 mmHg
    • A mean pulmonary arterial pressure (PAP) of >20 mmHg.
  7. Participants must have a 6-minute walk distance ≥100 meters and ≤500 meters at the Screening Visit (Visit 1).

  8. Participants agree to a repeat RHC, Chest CT, and MRI prior to study completion.

  9. Participants on chronic treatment for underlying lung disease (i.e., nintedanib or pirfenidone or immunosuppressive agents etc.) must be on a stable/optimized dose for ≥30 days prior to screening and have been receiving treatment for ≥90 days.

  10. Participants on supportive medications (e.g., inhalers for asthma) must be on stable doses for ≥30 days prior to screening.

  11. In the Investigator's opinion, the participant must be able to consent for themselves and communicate with local staff using interpreters if necessary. Participants must agree to attend all study visits and be contactable through a cellular device or landline.

  12. Participants must have clinical laboratory values within normal ranges or <1.5 times the upper limit of normal (ULN) as specified by the testing laboratory.

  13. Participants must meet the following requirements for the pulmonary function test (PFT) at screening:

    • Forced vital capacity (FVC) <90% of predicted
    • Diffusion capacity of carbon monoxide (DLCO) <70% of predicted, or <70% of predicted corrected for hemoglobin (Hb), if correction is required. (Correction applies if Hb value is ≥25% and ≤90% of normal.) Note: DLCO must be determined locally at screening, using American Thoracic Society (ATS) standards. Hemoglobin correction should reference ATS normal values: Men = 14.6 g/dL, Women = 13.4 g/dL.
  14. Negative serology test for hepatitis B surface antigen and hepatitis C antibody at Screening Visit.

Exclusion criteria:

Medical Conditions

  1. Participant has another concomitant diagnosis of pulmonary hypertension not otherwise considered to be PH-ILD. This would include and is not limited to the concomitant presence of thromboembolic disease, untreated/inadequately treated obstructive sleep apnea, human immunodeficiency virus (HIV), methamphetamine or anorexigenic drug use, and other conditions of the WHO Group 1, 2, 4, and 5 classifications.

  2. Participant has evidence of clinically significant left-sided heart disease within 6 months of screening as defined by:

    • Left ventricular ejection fraction <40% as assessed by echocardiography.
    • More than mild left-sided valvulopathy (e.g., worse than mild mitral stenosis or regurgitation and worse than mild aortic stenosis or regurgitation).
    • LVEDP or PCWP >15 mmHg (or >12 mmHg if PVR ≥4 to 6.25 Wood units).
  3. Participants must NOT have 3 or more of the following left ventricular disease/dysfunction risk factors at screening:

    • Body mass index (BMI) ≥30 kg/m2.

    • Uncontrolled diabetes, as evidenced by HbA1C >9.5%, or urine glycosuria >1.0 g/dl, or presence of diabetic ketoacidosis.

    • History of significant coronary disease within 6 months of screening as demonstrated by any of the following:

      1. History of myocardial infarction or acute coronary syndrome (unstable angina), or
      2. Percutaneous coronary intervention or percutaneous transluminal angioplasty, or previous coronary artery bypass graft, or
      3. Evidence of coronary artery disease (>50% stenosis in at least one major coronary artery) or abnormal nuclear stress test.
  4. The participant is receiving ≥10 L/min of oxygen supplementation by any mode of delivery at rest.

  5. The participant has received any PH-approved therapy, including soluble guanylate cyclase inhibitors, endothelin receptor antagonists, or parenteral or oral prostacyclin therapy (excluding vasoreactivity testing) within 60 days of randomization or 5 half-lives. Use of phosphodiesterase type 5 inhibitors and inhaled prostacyclin (e.g., inhaled treprostinil) on stable doses for ≥30 days prior to screening will be allowed irrespective of local approval (as per ESC/ERS 2022).

  6. Use of any inhibitors and inducers of cytochrome P450 3A4 (CYP3A4) (e.g., boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, telaprevir, tipranavir and ritonavir, telithromycin, troleandomycin, voriconazole, clarithromycin, idelalisib, nefazodone, nelfinavir, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort). For a comprehensive list, please refer to the FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems (FDA 2025).

  7. Recent exacerbation of underlying lung disease or active pulmonary/upper respiratory tract infection within 4 weeks of randomization.

  8. Any current active malignancy (this does not include localized cancers such as basal or squamous cell carcinoma of the skin). Any history of malignancy that is likely to result in mortality or require significant medical or surgical intervention within the following year.

  9. Chronic kidney disease Stage IV or greater (i.e., eGFR ˂30 mL/min/1.73m2) or evidence of acute kidney injury.

  10. The participant has a history of congenital heart disease, irrespective of any prior treatment or surgical intervention

  11. Use of tobacco, e-cigarette, nicotine, or marijuana products or a significant history of drug or alcohol abuse within 6 months of screening.

  12. Acute pulmonary embolism within 90 days of screening.

  13. Participation in pulmonary rehabilitation within 90 days of screening. However, participants who were on stable pulmonary rehabilitation for more than 90 days before screening may be considered for the study, provided they meet all other inclusion criteria.

  14. Prior or concurrent use of any investigational drug/device/therapy or participation in any investigational study with therapeutic intent within 30 days or 5 half-lives, whichever is longer, before the first dose of the IP.

  15. BMI ≥40 kg/m2.

  16. Uncontrolled hypertension as evidenced by systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg during the screening period. Participants who fail screening due to high blood pressure can be re-screened once after their antihypertensive medications have been adjusted and their doses have been stable for at least 4 weeks.

  17. Concomitant disease that confers a life expectancy of <6 months at screening.

  18. The Investigator judges that the participant will be unable to fully participate in the study and complete it for any reason, including inability to comply with the study procedures and treatment of addiction or any other relevant medical or psychiatric conditions.

  19. High likelihood of lung transplantation (in the opinion of the Investigator) within 4 months after randomization.

  20. History of liver dysfunction, including participants with moderate (Child-Pugh B) or severe (Child-Pugh C) impairment or disordered coagulation.

  21. Female participants who are pregnant or breastfeeding.

  22. Worse than mild untreated sleep apnea (5-14.9 events/hour). Treated sleep apnea is permitted.

  23. Participants with a prior diagnosis of connective tissue diseases, e.g., systemic sclerosis (scleroderma), systemic lupus erythematosus, Sjogren's disease, polymyositis/dermatomyositis/antisynthetase syndrome, or rheumatoid arthritis.

    Other Exclusions

  24. History of allergic or anaphylactic reaction to mirivadelgat or to any component of the excipient.

  25. Previous exposure to mirivadelgat.

    Diagnostic Assessments

  26. The following laboratory parameters are excluded:

    • Hemoglobin <10 g/dL (100 g/L).
    • White blood cells (WBC) <3000/µL (<3000/mm3).
    • Platelet count <70,000/µL (70,000/mm3).
    • Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 or evidence of acute kidney injury.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:150 mg mirivadelgat

150 mg mirivadelgat once daily

Selective aldehyde dehydrogenase 2 (ALDH2) activator

他の名前:
  • FP-045
実験的:300 mg mirivadelgat

300 mg mirivadelgat once daily

Selective aldehyde dehydrogenase 2 (ALDH2) activator

他の名前:
  • FP-045
プラセボコンパレーター:placebo

placebo once daily

placebo

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pulmonary Vascular Resistance (PVR)
時間枠:12 weeks

The mean change from baseline to Week 12 in PVR assessed by right heart catheterization (RHC) for mirivadelgat vs. placebo.

12 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
6-minute walk distance
時間枠:12 weeks

The mean change from baseline to Week 12 in the 6-minute walk distance

12 weeks
Time to clinical deterioration from baseline to Week 12 for any of the following ADJUDICATED clinical events
時間枠:12 weeks
  • Death (all-cause mortality).
  • Hospital admission greater than 24 hours due to worsening of pulmonary hypertension.
  • Worsening of pulmonary hypertension resulting in the need for lung transplant or balloon atrial septostomy.
  • Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary hypertension-specific therapies, or need for an increase of diuretics for more than 4 weeks due to worsening of pulmonary hypertension.
  • Disease progression.
  • A decrease of more than 15% from the baseline in the 6-minute walk distance test combined with World Health Organization (WHO) functional class III or IV symptoms at 2 consecutive visits separated by at least 7 days.
12 weeks
Long-term prognostic risk factors
時間枠:12 weeks

The mean change from baseline to Week 12 of long-term prognostic risk factors of plasma/serum N-terminal pro-brain natriuretic peptide (NT-ProBNP), C-terminal procollagen I (PICP), N-terminal procollagen I (NICP or PINP), and N-terminal procollagen III (NIIICP or PIIINP).

12 weeks
Patient-reported outcome measures (PROMS): (SF)-36v2
時間枠:12 weeks

The change from baseline to Week 12 in the Short Form (SF)-36v2 Health Survey with Scale 0 to 100 (mean is 50), 0 is worst, 100 is best

12 weeks
Patient-reported outcome measures (PROMS): WIQ
時間枠:12 weeks

The change from baseline to Week 12 in the Walking Impairment Questionnaire (WIQ) with percentage scale ranging from 0% (worst) to 100% (best)

12 weeks
Patient-reported outcome measures (PROMS): PAH-SYMPACT
時間枠:12 weeks

The change from baseline to Week 12 in the Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire (PAH-SYMPACT) with each point scored from 0 (best) to 4 (worst)

12 weeks

その他の成果指標

結果測定
メジャーの説明
時間枠
Inflammatory markers
時間枠:12 weeks

The mean change in concentration of inflammatory markers interleukin-6 (IL-6), high-sensitivity C-reactive protein (HS-CRP), and tumor necrosis factor- α (TNF-α) from baseline to Week 12.

12 weeks
Change in Biomarkers
時間枠:Week 12

The mean change in biomarkers related to fibrogenesis, inflammation, tissue destruction, and epithelial damage, including but not limited to PRO-C3, PRO-C6, C1M, C3M, C6M, C4Malph3, VICM, and CC16-HNE, from baseline to Week 12

Week 12
Cardiac MRI fibrosis score
時間枠:12 weeks

The mean change in cardiac MRI fibrosis score assessed by cardiac MRI gadolinium enhancement from baseline to Week 12 with a continuous variable that is not presented on a scale (only for subjects who have no contraindication to MRI procedure).

12 weeks
Quantitative ILD features
時間枠:12 weeks

The change in Quantitative ILD features [i.e., Ground glass (QGC), Lung fibrosis (QLF), and Honeycombing (QHC)] assessed by HRCT scan from baseline to Week 12.

12 weeks
Risk for intervention
時間枠:12 weeks

The Absolute Risk for intervention regarding specific events of death and stroke (CVA) (the absolute risk reduction between placebo and treatment of the composite event of death and stroke)

12 weeks
Change of right ventricle/left ventricle (RV/LV) size
時間枠:12 weeks

The mean change in transthoracic echocardiography measurement of right ventricle/left ventricle (RV/LV) size, function, and strain from baseline to Week 12.

12 weeks
Pulmonary function tests (PFTs) - FEV1
時間枠:12 weeks

The change in FEV1 from baseline to Week 12.

12 weeks
Pulmonary function tests (PFTs) - FEV1 / FVC ratio and diffusion capacity of carbon monoxide (DLCO)
時間枠:12 weeks

The change in FEV1 / FVC and DLCO from baseline to Week 12.

12 weeks
Pharmacokinetic (PK) parameters: T1/2
時間枠:12 weeks

T1/2 for mirivadelgat and its active metabolite AD-835.

12 weeks
Pharmacokinetic (PK) parameters: AUC
時間枠:12 weeks

AUC for mirivadelgat and its active metabolite AD-835.

12 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • スタディディレクター:Bassem Elmankabadi, MD、Foresee Pharmaceuticals

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年3月1日

一次修了 (推定)

2028年2月1日

研究の完了 (推定)

2028年2月1日

試験登録日

最初に提出

2024年6月12日

QC基準を満たした最初の提出物

2024年6月19日

最初の投稿 (実際)

2024年6月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月21日

QC基準を満たした最後の更新が送信されました

2026年9月17日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • FP-045C-23-001

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する